Neuroscience

Areas of Interest

Treatment Resistant Depression – Major Depressive Disorder with inadequate response to 2 or more antidepressants

• Definition, patient identification, patient characteristics
• Evidence based-treatment paradigms
• Mechanistic rationale to treatment approaches
• Current and future disease management trends
• Innovation and technology for disease management
• Disease burden and overcoming treatment access challenges
• Impact in underserved communities and populations
• Allied health professional’s role in the disease management

Areas of Interest

• Disease state education
  • Patient and caregiver education on disease and disease management
  • Brain volume loss
  • Racial healthcare disparities in patients with MS
• Updates on current therapeutic options and treatment paradigms
  • S1Ps (early use, rapid reversibility, discontinuations, MOA, drug interactions, vaccination)
  • DMTs (switching, subgroup responsiveness, use in pregnancy, vaccination)
• Allied Health Profession's role in management of patients with MS
• COVID-19

Areas of Interest

• Antipsychotic long acting injectables (LAI) transition of care models (inpatient to outpatient)
• First-Episode Psychosis – Model of Care for introducing atypical antipsychotic LAIs early in treatment, including patient engagement strategies addressing acceptance and satisfaction
• Outcomes measures - Earlier use of atypical antipsychotic LAIs in early use psychosis clinics (clinical and psychosocial outcomes)
• Patterns of atypical antipsychotic LAI utilization in underserved communities and populations
• Effects and dynamics of the treatment coalition in adopting atypical antipsychotic LAI utilization earlier in schizophrenia treatment journey
• Competency models assessing injection techniques in the administration of atypical antipsychotic LAIs

Please click here to view the certificate of separation

Click here to submit an Independent Medical Education Grant